Biohaven Ltd

BHVN

$47.31

Closing

▼-0.04%

1D

▲10.54%

YTD

Market cap

$3.74B

52 week high

$50.60

52 week low

$12.38

Volume

216,452

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$3.74B

Analysts' Rating

BUY

Price Target (Mean)

33.66667

Total Analysts

7

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

0.00%

52 week high

$50.60

52 week low

$12.38

Div. Yield

%

EPS Annual Growth

13.64

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder (OCD) and Spinocerebellar Ataxia (SCA), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for immune-mediated brain disorders. Its portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and extracellular target degrader platform technology (MoDE) with potential application in neurological disorders, cancer, and autoimmune diseases.